News Releases

UB-developed scoring system lays groundwork for North America’s first test to predict therapeutic resistance for the rare, but severe disease.

Recently published paper suggests that ‘hypergraphs’ better explain how neuronal networks communicate.

The results of a clinical trial on the drug semaglutide in teens, released in the New England Journal of Medicine, turned out to be better than anything the participants — or even the researchers — expected.

The $15 million National Science Foundation program will foster innovation and accelerate economic development in Western New York, and beyond.

Channavix Therapeutics and Peregrine BioVentures are developing two patent families related to long-lasting, non-opioid, non-addictive pain therapeutics.

Even with varenicline, most people return to smoking within six months of quitting.

Initiative aims to improve health outcomes in neighborhoods whose residents are more likely to experience chronic, serious diseases. 

The university expects to resume normal operations starting Sunday.

The cancellation is in effect for all three campuses.

The UB researchers who have changed the way concussions are treated have been awarded a grant to conduct a clinical trial to take their Buffalo Concussion Protocol  and apply it to the military environment.